Search results for "Cell Cycle"

showing 10 items of 804 documents

Multiple, alternative cleavage patterns precede uniform larval morphology during normal development of Dreissena polymorpha (Mollusca, Lamellibranchi…

1995

In this study we reinvestigate the early development of the freshwater mussel Dreissena polymorpha, previously studied by Meisenheimer (1901). The data include video time-lapse recordings of living embryos and bisbenzimide stains of fixed embryos as well as morphometry on fixed, serially-sectioned embryos. We present the cell lineage and cell cycle durations up to the first indication of symmetrization within this embryo. We show that early cell cycles last approximately 1h. A dramatic extension of cell cycle duration and a concomitant asynchrony among the various cell lines was observed starting at the fifth cleavage. Short cell cycles, like those of early blastomeres, were a constant prop…

BisbenzimideEmbryoBlastomereAnatomyCell cycleBiologyCleavage (embryo)Embryonic stem cellCell biologychemistry.chemical_compoundSinistral and dextralchemistryGeneticsDevelopmental biologyDevelopmental BiologyRoux's Archives of Developmental Biology
researchProduct

Differentiative pathway activated by 3-aminobenzamide, an inhibitor of PARP, in human osteosarcoma MG-63 cells

2004

AbstractThis study describes the molecular mechanism by which treatment with 3-AB, a potent inhibitor of PARP, allows human osteosarcoma MG-63 cells to restrict growth and enter differentiation. Our findings show that in MG-63 cells, aberrant gene expression keeps Rb protein constitutively inactivated through hyperphosphorylation and this promotes uncontrolled proliferation of the cells. After 3-AB-treatment, the poly(ADP-ribosyl)ation of nuclear proteins markedly decreases and this results in an increase in both the hypophosphorylated active form of Rb and pRb/E2F complexes. These effects are accompanied by G1 arrest, downregulation of gene products required for proliferation (cyclin D1, β…

Blotting WesternBiophysicsHyperphosphorylationCell Cycle ProteinsPoly(ADP-ribose) Polymerase InhibitorsCell cycleRetinoblastoma ProteinBiochemistryPARPRb proteinCyclin D1Downregulation and upregulationStructural BiologyCell Line TumorGene expressionGeneticsHumansImmunoprecipitationOsteopontinEnzyme InhibitorsPhosphorylationE2FMolecular BiologyDNA PrimersAdenosine Diphosphate RiboseOsteosarcomaBase SequencebiologyReverse Transcriptase Polymerase Chain ReactionG1 PhaseCell DifferentiationCell BiologyCell cycleFlow Cytometry3-ABE2F Transcription FactorsChromatinDNA-Binding ProteinsGene Expression RegulationDifferentiationBenzamidesbiology.proteinCancer researchTranscription FactorsFEBS Letters
researchProduct

The transcriptional programme of contact-inhibition.

2010

Proliferation of non-transformed cells is regulated by cell-cell contacts, which are referred to as contact-inhibition. Vice versa, transformed cells are characterised by a loss of contact-inhibition. Despite its generally accepted importance for cell-cycle control, little is known about the intracellular signalling pathways involved in contact-inhibition. Unravelling the molecular mechanisms of contact-inhibition and its loss during tumourigenesis will be an important step towards the identification of novel target genes in tumour diagnosis and treatment. To better understand the underlying molecular mechanisms we identified the transcriptional programme of contact-inhibition in NIH3T3 fib…

Blotting WesternClone (cell biology)Cell Cycle ProteinsBiologyBiochemistryMiceComplementary DNATranscriptional regulationAnimalsMolecular BiologyGeneRegulator geneOligonucleotide Array Sequence AnalysisContact InhibitionReverse Transcriptase Polymerase Chain ReactionGene Expression ProfilingCell CycleContact inhibitionCell BiologyFibroblastsFlow CytometryMolecular biologyGene expression profilingNIH 3T3 CellsDNA microarraySignal TransductionJournal of cellular biochemistry
researchProduct

Preclinical evaluation of antitumor activity of the proteasome inhibitor MLN2238 (ixazomib) in hepatocellular carcinoma cells

2017

AbstractHepatocellular carcinoma (HCC) is one of the common malignancies and is an increasingly important cause of cancer death worldwide. Surgery, chemotherapy, and radiation therapy extend the 5-year survival limit in HCC patients by only 6%. Therefore, there is a need to develop new therapeutic approaches for the treatment of this disease. The orally bioavailable proteasome inhibitor MLN2238 (ixazomib) has been demonstrated to have anticancer activity. In the present study, we investigated the preclinical therapeutic efficacy of MLN2238 in HCC cells through in vitro and in vivo models, and examined its molecular mechanisms of action. MLN2238 inhibited cell viability in human HCC cells He…

Boron Compounds0301 basic medicineCancer ResearchCarcinoma HepatocellularMyeloidCell cycle checkpointImmunologyCellGlycineAntineoplastic AgentsArticleIxazomibAntineoplastic AgentMice03 medical and health sciencesCellular and Molecular Neurosciencechemistry.chemical_compound0302 clinical medicinemedicineAnimalsHumansViability assaylcsh:QH573-671Boron CompoundAnimallcsh:Cytologybusiness.industryLiver NeoplasmsCell Biologydigestive system diseases3. Good health030104 developmental biologymedicine.anatomical_structurechemistryLiver NeoplasmCell cultureApoptosis030220 oncology & carcinogenesisProteasome inhibitorCancer researchbusinessProteasome InhibitorsHumanmedicine.drugCell Death & Disease
researchProduct

Hematopoietic Stem Cells Reversibly Switch from Dormancy to Self-Renewal during Homeostasis and Repair

2008

Bone marrow hematopoietic stem cells (HSCs) are crucial to maintain lifelong production of all blood cells. Although HSCs divide infrequently, it is thought that the entire HSC pool turns over every few weeks, suggesting that HSCs regularly enter and exit cell cycle. Here, we combine flow cytometry with label-retaining assays (BrdU and histone H2B-GFP) to identify a population of dormant mouse HSCs (d-HSCs) within the lin(-)Sca1(+)cKit(+)CD150(+)CD48(-)CD34(-) population. Computational modeling suggests that d-HSCs divide about every 145 days, or five times per lifetime. d-HSCs harbor the vast majority of multilineage long-term self-renewal activity. While they form a silent reservoir of th…

BromouracilProliferationCellCD34CELLCYCLEQuiescenceSelf renewalMice0302 clinical medicineLongBone MarrowHomeostasisCancereducation.field_of_study0303 health sciencesProgenitor Cellshemic and immune systemsCell cycleCell biologyAdult Stem CellsHaematopoiesismedicine.anatomical_structure030220 oncology & carcinogenesisFluorouracilStem cellGreen Fluorescent ProteinsPopulationMice TransgenicCycleBiologyGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesmedicineAnimalsProgenitor celleducationUridine030304 developmental biologyMouse ModelBiochemistry Genetics and Molecular Biology(all)Osteoblastic NicheHematopoietic Stem CellsSTEMCELLAntigens DifferentiationMarrowIn-VitroImmunologyDormancyBone marrowHomeostasisCell
researchProduct

Id2 leaves the chromatin of the E2F4–p130-controlled c-myc promoter

2006

The Id (inhibitor of DNA binding or inhibitor of differentiation) helix–loop–helix proteins are involved in the regulation of cell growth, differentiation and cancer. The fact that the molecular mechanisms of liver regeneration are not completely understood prompted us to study the fate of Id2 in proliferating liver. Id2 increases in liver regeneration after partial hepatectomy, following the early induction of its gene. Co-immunoprecipitation shows that Id2 forms a complex with E2F4, p130 and mSin3A in quiescent liver and all these components are present at the c-myc promoter as shown using ChIP (chromatin immunoprecipitation). Activation of c-myc during hepatocyte priming (G0–G1 transitio…

C-mycLiver:CIENCIAS DE LA VIDA::Bioquímica [UNESCO]E2FCell cycle; C-myc; E2F; Histone deacetylase; Id2; LiverUNESCO::CIENCIAS DE LA VIDA::BioquímicaHistone deacetylaseId2Cell cycle
researchProduct

Difference in Ki67 and thymidylate synthase expression in primary tumour compared with metastatic nodes in breast cancer patients.

2005

Breast cancer is a heterogeneous disease, so therapeutic predictive biological markers need to be identified. To date an accurate evaluation of predictive markers is mainly done at the primary site; however, the main goal of adjuvant therapy for breast cancer is the control of micrometastases. The aim of this study is to assess as therapeutic and/or prognostic marker, the proliferation status of primary tumors and involved nodes as measured by Ki67 and thymidylate synthase (TS) expression, in 30 breast cancer node positive patients. TS is the main target of 5-fluorouracil (5-FU) activity, and its overexpression is one of the mechanisms of 5-FU drug resistance; however, in some studies its a…

CA15-3Antimetabolites AntineoplasticProliferation indexBreast NeoplasmsDiseaseDrug resistanceBiologySettore MED/08 - Anatomia PatologicaBiochemistryThymidylate synthaseGene Expression Regulation EnzymologicBreast cancerbreast cancerAntigens NeoplasmGeneticsmedicineAdjuvant therapyHumansNeoplasm MetastasisCell ProliferationGeneral MedicineThymidylate SynthaseCell cyclemedicine.diseasePrognosisGene Expression Regulation NeoplasticKi-67 AntigenmetastaseLymphatic MetastasisImmunologyCancer researchbiology.proteinMolecular MedicineFemaleFluorouracilKi67Nucleosides, nucleotidesnucleic acids
researchProduct

Histone deacetylase inhibition modulates deoxyribonucleotide pools and enhances the antitumor effects of the ribonucleotide reductase inhibitor 3’-C-…

2011

Histone deacetylase (HDAC) inhibitors are a new class of epigenetic agents that were reported to enhance the cytotoxic effects of classical anticancer drugs through multiple mechanisms. However, which of the possible drug combinations would be the most effective and clinically useful are to be determined. We treated the HL60 and NB4 promyelocytic leukaemia cells with a combination of the ribonucleotide reductase (RR) inhibitor 3'-C-methyladenosine (3'-Me-Ado) and several hydroxamic acid-derived HDAC inhibitors, including two recently synthesized molecules, MC1864 and MC1879, and the reference compound trichostatin A (TSA). The results showed significant growth inhibitory and apoptotic syner…

Cancer ResearchAdenosineHL60CellDeoxyribonucleotidesAntineoplastic AgentsApoptosisHL-60 CellsRibonucleotide reductase inhibitorBiologyHydroxamic AcidsHDAC inhibitors RR inhibitors Apoptosis Leukaemia ROSchemistry.chemical_compoundRibonucleotide ReductasesmedicineHumansCell ProliferationLeukemiaG1 PhaseCell cycleHistone Deacetylase InhibitorsRibonucleotide reductasemedicine.anatomical_structureTrichostatin AOncologychemistryApoptosisCancer researchSettore BIO/14 - FarmacologiaHistone deacetylaseReactive Oxygen Speciesmedicine.drug
researchProduct

Centrosome amplification induced by hydroxyurea leads to aneuploidy in pRB deficient human and mouse fibroblasts.

2006

Alterations in the number and/or morphology of centrosomes are frequently observed in human tumours. However, it is still debated if a direct link between supernumerary centrosomes and tumorigenesis exists and if centrosome amplification could directly cause aneuploidy. Here, we report that hydroxyurea treatment induced centrosome amplification in both human fibroblasts expressing the HPV16 -E6-E7 oncoproteins, which act principally by targeting p53 and pRB, respectively, and in conditional pRB deficient mouse fibroblasts. Following hydroxyurea removal both normal and p53 deficient human fibroblasts arrested. On the contrary pRB deficient fibroblasts entered the cell cycle generating aneupl…

Cancer ResearchAneuploidyCentrosome amplificationBiologymedicine.disease_causeRetinoblastoma ProteinCell LineMicepRBChromosomal InstabilitymedicineDeficient mouseAnimalsHumansHydroxyureaCINCells CulturedCentrosomeDNA synthesisCell cycleFibroblastsmedicine.diseaseAneuploidyCell biologySettore BIO/18 - GeneticaOncologyCentrosomeAneuploid CellsCarcinogenesisCancer letters
researchProduct

MYCN sensitizes human neuroblastoma to apoptosis by HIPK2 activation through a DNA damage response.

2010

Abstract MYCN amplification occurs in approximately 20% of human neuroblastomas and is associated with early tumor progression and poor outcome, despite intensive multimodal treatment. However, MYCN overexpression also sensitizes neuroblastoma cells to apoptosis. Thus, uncovering the molecular mechanisms linking MYCN to apoptosis might contribute to designing more efficient therapies for MYCN-amplified tumors. Here we show that MYCN-dependent sensitization to apoptosis requires activation of p53 and its phosphorylation at serine 46. The p53S46 kinase HIPK2 accumulates on MYCN expression, and its depletion by RNA interference impairs p53S46 phosphorylation and apoptosis. Remarkably, MYCN ind…

Cancer ResearchApoptosisCell Cycle ProteinsAtaxia Telangiectasia Mutated ProteinsProtein-Serine-Threonine KinaseAtaxia Telangiectasia Mutated ProteinNeuroblastomaCell Cycle ProteinSerinePhosphorylationNuclear ProteinOncogene Proteinseducation.field_of_studyN-Myc Proto-Oncogene ProteinAntibiotics AntineoplasticKinaseOncogene ProteinNuclear ProteinsDNA-Binding ProteinsOncologyPhosphorylationRNA InterferenceHumanDNA damageDNA-Binding ProteinPopulationBlotting WesternBiologyProtein Serine-Threonine KinasesN-Myc Proto-Oncogene ProteinBleomycinNeuroblastomaCell Line TumormedicineHumanseducationneoplasmsMolecular BiologyTumor Suppressor ProteinTumor Suppressor ProteinsApoptosimedicine.diseaseTumor progressionApoptosisMutationCancer researchTumor Suppressor Protein p53Carrier ProteinCarrier ProteinsDNA DamageMolecular cancer research : MCR
researchProduct